2 completed, 2 terminated, 2 withdrawn. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Terminated 2, Withdrawn 2 |
| Phase 1 | 1 | Completed 1 |
Follow hepatitis B hyperimmune globulin: new trials by email Literature Review of hepatitis B hyperimmune globulin trials Research Report on hepatitis B hyperimmune globulin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide - Lung Transplant, Hepatitis B | Phase 2 | Withdrawn | University of Pennsylvania | 2022-09-06 | 2024-08-06 | |
| Treatment of Patients With Chronic Hepatitis B With Hepatitis B Immunoglobulins Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®) - Chronic Hepatitis B | Phase 2 | Terminated | Hannover Medical School | 13 | 2022-08-15 | 2025-09-04 |
| Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B hepatitis B immune globulin (HBIg), Pegylated interferon alfa (pegIFN) - Chronic Hepatitis B | Phase 2 | Withdrawn | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2019-02-13 | 2022-04-06 | |
| Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant FTC/TDF, Hepatitis B Immunoglobulin (HBIg) - Chronic Hepatitis B | Phase 2 | Completed | Gilead Sciences | 40 | 2007-09-01 | 2014-03-14 |
| Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation Hepatitis B Immune Globulin (Boca HBVIg) - Hepatitis B Virus Associated Liver Disease | Phase 1 / Phase 2 | Completed | Biotest Pharmaceuticals Corporation | 30 | 1999-11-01 | 2019-01-22 |
| HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection HepeX-B, Hepatitis B Immune Globulin (HBIg) - Hepatitis B, Liver Transplantation | Phase 2 | Terminated | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2007-02-13 |
Hepatitis B (3) · Hepatitis B, Chronic (3) · Liver Diseases (1)
Biotest Pharmaceuticals Corporation (1) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Gilead Sciences (1) · Hannover Medical School (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · University of Pennsylvania (1)
United States (5) · Germany (2) · France (1) · Israel (1) · New Zealand (1) · Spain (1) · United Kingdom (1)
Andrew M Courtwright, MD, PhD (1) · Anna Lok, M.D. (1) · Consuelo Soldevila-Pico, M.D. (1) · Donald Jensen, M.D. (1) · Heiner Wedemeyer, Prof. (1) · Lewis Teperman, MD (1) · Marc G Ghany, M.D. (1) · Michael Fried, M.D. (1) · Michael Ishitani, M.D. (1) · Norah A. Terrault, M.D., MPH (1) · Patricia Sheiner, M.D. (1) · Rajender Reddy, M.D. (1) · Robert S. Brown, M.D., MPH (1) · Rolland C. Dickson, M.D. (1) · Terence Angtuaco, M.D. (1)